The SARAH study has been awarded an Oral Abstract at the meeting and will be presented in the General Session III on Saturday, 22nd April 2017 between 10-10:15 am local time. The Oral Abstract is entitled “SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma.”